PP
ARQT icon

PDT Partners’s Arcutis Biotherapeutics ARQT Stock Holding History

PDT Partners’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.07M Hold
155,075
– – 0.21% 154
2026
Q1 		$3.65M Hold
155,075
– – 0.22% 156
2025
Q4 		$4.5M Buy
155,075
+967
+0.6% +$24.8K 0.29% 117
2025
Q3 		$2.9M Sell
154,108
-36,875
-19% -$582K 0.18% 194
2025
Q2 		$2.68M Sell
190,983
-126,482
-40% -$1.77M 0.15% 235
2025
Q1 		$4.97M Sell
317,465
-2,250
-0.7% -$31.7K 0.35% 72
2024
Q4 		$4.45M Hold
319,715
– – 0.39% 52
2024
Q3 		$2.97M Hold
319,715
– – 0.26% 118
2024
Q2 		$2.97M Sell
319,715
-511
-0.2% -$4.62K 0.28% 112
2024
Q1 		$3.17M Buy
+320,226
New +$2.39M 0.3% 102
2023
Q4 		– Sell
-195,081
Closed -$1.04M – 541
2023
Q3 		$1.04M Buy
195,081
+74,503
+62% +$634K 0.13% 275
2023
Q2 		$1.15M Sell
120,578
-34,906
-22% -$387K 0.16% 218
2023
Q1 		$1.71M Buy
155,484
+97,607
+169% +$1.41M 0.23% 155
2022
Q4 		$857K Buy
57,877
+45,204
+357% +$790K 0.14% 267
2022
Q3 		$242K Buy
+12,673
New +$287K 0.04% 656

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

PDT Partners's ARQT Position: Q2 2026 in Review

PDT Partners held its Arcutis Biotherapeutics (ARQT) position steady in Q2 2026 at 155,075 shares worth $4.07M. The position accounts for 0.21% of the portfolio, ranked #154.

PDT Partners first reported a position in ARQT in Q3 2022 and has held it in 15 quarters since. The position peaked at $4.97M in Q1 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • PDT Partners held 155,075 shares of Arcutis Biotherapeutics worth $4.07M as of Q2 2026.
  • PDT Partners left its Arcutis Biotherapeutics share count unchanged in Q2 2026.
  • Arcutis Biotherapeutics made up 0.21% of PDT Partners's portfolio in Q2 2026, its #154 holding.
  • PDT Partners first reported a position in Arcutis Biotherapeutics in Q3 2022 and has held it in 15 quarters since.
  • PDT Partners's Arcutis Biotherapeutics position peaked at $4.97M in Q1 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on PDT Partners's 13F filing for Q2 2026, filed 14 Aug 2026.